【異動股】四環醫藥再有腫瘤藥獲准作臨床試驗 曾急升一成創歷史高位 – 香港經濟日報 – 即時新聞頻道 – iMoney智富 – 股樓投資 2021-06-03T04:54:22-04:00June 3rd, 2021| share this article! 四環醫藥（00460）旗下的軒竹生物自主研發的新藥XZP-5955，獲批准作藥物臨床試驗。這是繼集團在1月XZP-5610獲得臨床試驗批准後，另一個批開展臨床試驗的創新藥物。 煤氣料今年業績勝去年 重 Read More share this article! Related Posts US law firm Mayer Brown to call off Hong Kong partnership May 2nd, 2024 Australia’s second-largest pension fund blacklists thermal coal investments May 2nd, 2024 India’s Vodafone Idea in talks to avail $1.8b loans over two years May 2nd, 2024 AI-SaaS company AiDash closes Series C round at $58.5m led by Lightsmith Group May 2nd, 2024
